Beacon Therapeutics Raises $170 Million in Series B Funding to Advance Development of Ophthalmic Gene Therapies
Beacon Therapeutics, a leading ophthalmic gene therapy company that acquired UF startup AGTC to save and restore the vision of patients with blinding retinal diseases, announced it has raised $170 million in Series B funding.
Tech Tuesday: A Helpful Virus
In this week's Tech Tuesday for WCJB TV20, UF Innovate's Melanie Morón interviews Dr. Arun Srivastava from the University of Florida's College of Medicine Department of Pediatrics who introduces us to a virus -- the adeno-associated virus or AAV -- that cures rather than infects. AAV has cured nine human diseases. The FDA has approved five drugs using it. And Dr. Srivastava's lab of scientists is working to make the vectors more efficient.
